### Vancomycin

**Indication**: Endophthalmitis  
**ICD11 code**: 9C21

**INN**: Vancomycin

**Medicine type**: Chemical agent

**Antibiotic groups**: WATCH

**List type**: Core

**Formulations**: Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

**EML status history**:  
First added in 2021 (TRS 1035)  
Changed in 2023 (TRS 1049)

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Patents have expired in most jurisdictions  
[Read more about patents.](#)

**Wikipedia**: [Vancomycin](#)

**DrugBank**: [Vancomycin](#)

---

### Expert Committee recommendation

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:  
- The addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.  
- The addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

### EML recommendations: Endophthalmitis

**First choice**

- ceftazidime

co-prescribed with [vancomycin](#)

**Second choice**

- ceftriaxone

co-prescribed with [vancomycin](#)